You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chimeric Antigen Receptor (CAR) T-cell Therapy Services

Chimeric antigen receptor (CAR) T-cell therapy is a new treatment for some types of leukemia and lymphoma. CAR T-cell therapy is a type of immunotherapy called “adoptive T-cell immunotherapy.” Immunotherapy uses a person’s own immune cells to fight cancer. CAR T-cell therapy reprograms the genetics of a person’s immune cells to find and attack cancer cells throughout their body.

The process to produce and deliver CAR T-cell therapy is complex. This quickly evolving area of cancer care requires specialized expertise, and is only available at select hospitals in Ontario.

Our Role

We provide provincial oversight for the planning and delivery of CAR T-cell therapy services in Ontario. This includes:

  • funding CAR T-cell therapy at specialized centres
  • monitoring emerging data and evidence, and adjusting provincial plans and approaches accordingly

Four hospitals in Ontario provide CAR T-cell therapy for a limited number of pediatric and adult patients from Ontario, and other provinces and territories.